Upgrade to SI Premium - Free Trial

Arrowhead Pharmaceuticals Inc. (ARWR)

86.34 -0.15 (0.17%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/30/26)

Latest Headlines

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26' September 1, 2026 9:07 AM - StreetInsider Stifel Reiterates Buy Rating on Arrowhead Pharma (ARWR) August 31, 2026 9:21 AM - StreetInsider RBC Capital Reiterates Outperform Rating on Arrowhead Pharma (ARWR) August 31, 2026 8:40 AM - StreetInsider Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data August 30, 2026 11:30 AM - StreetInsider Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia August 30, 2026 11:30 AM - BizWire Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress August 24, 2026 7:30 AM - BizWire Form 4 ARROWHEAD PHARMACEUTICAL For: Aug 18 Filed by: OLUKOTUN ADEOYE Y August 20, 2026 5:26 PM - SEC Filing Form 4 ARROWHEAD PHARMACEUTICAL For: Aug 18 Filed by: PERRY MICHAEL S August 20, 2026 5:22 PM - SEC Filing Form 144 ARROWHEAD PHARMACEUTICAL Filed by: OLUKOTUN ADEOYE Y August 18, 2026 5:34 PM - SEC Filing Form 144 ARROWHEAD PHARMACEUTICAL Filed by: PERRY MICHAEL S August 18, 2026 5:25 PM - SEC Filing People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides August 17, 2026 9:33 AM - BizWire Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: Avoro Capital Advisors LLC August 14, 2026 9:01 AM - SEC Filing Arrowhead Pharma (ARWR) PT Raised to $104 at Stifel August 5, 2026 8:19 AM - StreetInsider Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 16c August 4, 2026 4:26 PM - StreetInsider Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 16c August 4, 2026 4:11 PM - StreetInsider Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 04 August 4, 2026 4:03 PM - SEC Filing Form 10-Q ARROWHEAD PHARMACEUTICAL For: Jun 30 August 4, 2026 4:03 PM - SEC Filing Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results August 4, 2026 4:01 PM - BizWire Arrowhead Pharmaceuticals buys FDA priority review voucher for plozasiran August 4, 2026 4:00 PM - StreetInsider Arrowhead buys FDA priority review voucher for plozasiran sNDA August 4, 2026 4:00 PM - StreetInsider Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher August 4, 2026 4:00 PM - BizWire Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) August 3, 2026 4:30 PM - BizWire Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC July 31, 2026 11:21 AM - SEC Filing Arrowhead Pharma (ARWR) PT Raised to $123 at B.Riley July 30, 2026 8:47 AM - StreetInsider Arrowhead Pharma (ARWR) PT Raised to $100 at RBC Capital July 29, 2026 6:29 AM - StreetInsider Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: BlackRock, Inc. July 27, 2026 4:27 PM - SEC Filing Arrowhead completes enrollment in Phase 3 HoFH drug trial July 27, 2026 7:30 AM - StreetInsider Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia July 27, 2026 7:30 AM - BizWire Arrowhead Pharma (ARWR) PT Raised to $115 at H.C. Wainwright July 27, 2026 6:47 AM - StreetInsider Arrowhead Pharma (ARWR) PT Raised to $120 at Morgan Stanley July 23, 2026 8:42 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR) July 23, 2026 7:10 AM - StreetInsider Arrowhead Pharma (ARWR) PT Raised to $126 at Piper Sandler July 23, 2026 6:51 AM - StreetInsider Arrowhead's plozasiran hits Phase 3 endpoints in triglyceride study July 22, 2026 7:30 AM - StreetInsider Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia July 22, 2026 7:30 AM - BizWire Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results July 21, 2026 7:30 AM - BizWire Stifel Starts Arrowhead Pharma (ARWR) at Buy July 13, 2026 4:07 PM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Arrowhead Pharma (ARWR) July 2, 2026 6:43 AM - StreetInsider EU approves Arrowhead's plozasiran for rare triglyceride disorder June 22, 2026 12:36 PM - StreetInsider Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) June 22, 2026 12:33 PM - BizWire Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars June 18, 2026 7:30 AM - BizWire Form 4 ARROWHEAD PHARMACEUTICAL For: Jun 15 Filed by: Cohen Matthew Gregory June 17, 2026 9:44 PM - SEC Filing Form 3 ARROWHEAD PHARMACEUTICAL For: Jun 15 Filed by: Cohen Matthew Gregory June 17, 2026 9:44 PM - SEC Filing Arrowhead Pharmaceuticals appoints Dr. Matt Cohen to its board of directors June 16, 2026 4:07 PM - StreetInsider Form 8-K ARROWHEAD PHARMACEUTICAL For: Jun 12 June 16, 2026 4:03 PM - SEC Filing Full Article List